Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  van der Meijden, Paola E J ^a   Bouman, Annemieke C ^a   Feijge, Marion A H ^a   van Oerle, René ^a   Spronk, Henri M H ^a   Hamulyák, Karly ^b   ten Cate Hoek, Arina J ^a   ten Cate, Hugo ^a   Heemskerk, Johan W M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; ARACHIDONIC ACID; COLLAGEN; RISTOCETIN; VON WILLEBRAND FACTOR;

AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CARDIOMYOPATHY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; EPISTAXIS; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIGHT TRANSMISSION AGGREGOMETRY; LUNG EMBOLISM; MALE; MEASUREMENT; MUSCLE BLEEDING; PREDICTIVE VALUE; RECURRENT DISEASE; RETROSPECTIVE STUDY; SKIN BLEEDING; THROMBIN GENERATION; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOSIS; URINARY TRACT HEMORRHAGE; VALVULAR HEART DISEASE;

AGED; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; HEMORRHAGE; HUMANS; INTEGRINS; MALE; PLATELET AGGREGATION; RECURRENCE; THROMBIN; THROMBOSIS; VITAMIN K; VON WILLEBRAND FACTOR;

EID: 84878388914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064112     Document Type: Article

References (38)

1. Adriaansen HJ, de Bruijn-Wentink A (2010) Federation of Dutch Thrombosis Services; Summary medical year report 2010. [cited 2012 December]; Available: http://www.fnt.nl/media/docs/jaarverslagen/Jaarverslag_FNT_ Medisch_2010.pdf.
2. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, et al. (2012) Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e152S-184S.
3. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, et al. (2012) Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e44S-88S.
4. Federatie van Nederlandse Trombosediensten (2011) De kunst van het doseren. [cited 2013 February]; Available: http://www.fnt.nl/media/docs/overig/de_kunst_van_doseren.pdf.
5. Schulman S, Beyth RJ, Kearon C, Levine MN, (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S.
6. Palareti G, Cosmi B, (2009) Bleeding with anticoagulation therapy: who is at risk, and how best to identify such patients. Thromb Haemost 102: 268-278.
7. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, et al. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 348: 423-428.
8. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J, (2005) Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 128: 513-519.
9. Hayward CP (2005) Diagnosis and management of mild bleeding disorders. Hematology Am Soc Hematol Educ Program: 423-428.
10. Hayward CP, (2008) Diagnostic approach to platelet function disorders. Transfus Apher Sci 38: 65-76.
11. James PD, Goodeve AC, (2011) von Willebrand disease. Genet Med 13: 365-376.
12. Dentali F, Douketis JD, Lim W, Crowther M, (2007) Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 167: 117-124.
13. Schalekamp T, Klungel OH, Souverein PC, de Boer A, (2008) Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 100: 1076-1083.
14. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, et al. (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374: 1967-1974.
15. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, et al. (2012) Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126: 1185-1193.
16. Dawood BB, Lowe GC, Lordkipanidze M, Bem D, Daly ME, et al. (2012) Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood doi: 10.1182/blood-2012-07-444281.
17. Siljander P, Farndale RW, Feijge MA, Comfurius P, Kos S, et al. (2001) Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol 21: 618-627.
18. Federatie van Nederlandse Trombosediensten (2009) Indicatie- Rangordetabel FNT, oktober 2009. [cited 2012 December]; Available: http://www.fnt.nl/media/docs/tabellen/Rangordetabel_FNT_oktober_2009.pdf.
19. Van der Meijden PE, van Schilfgaarde M, van Oerle R, Renné T, ten Cate H, et al. (2012) Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 10: 1355-1362.
20. Spronk HM, Dielis AW, De Smedt E, van Oerle R, Fens D, et al. (2008) Assessment of thrombin generation II: validation of the calibrated automated thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 100: 362-364.
21. Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, et al. (1995) ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 68: 236-240.
22. Clinical and Laboratory Standards Institute, Christie DJ, Avari T, Carrington LR, Cohen E, et al (2008) Platelet function testing by aggregometry; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA, USA. 28: 1-45.
23. Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, et al. (2009) Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 7: 676-684.
24. Nurden P, Nurden AT, (2008) Congenital disorders associated with platelet dysfunctions. Thromb Haemost 99: 253-263.
25. Dawood BB, Wilde J, Watson SP, (2007) Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A2 pathways. Platelets 18: 329-345.
26. Snoep JD, Gaussem P, Eikenboom JC, Emmerich J, Zwaginga JJ, et al. (2010) The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. J Thromb Haemost 8: 2377-2384.
27. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J, (1990) Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 21: 47-51.
28. Lip GY, Lowe GD, Rumley A, Dunn FG, (1995) Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 73: 527-533.
29. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY, (2003) Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107: 3141-3145.
30. Lind M, Boman K, Johansson L, Nilsson TK, Jarvholm LS, et al. (2012) Von Willebrand factor predicts major bleeding and mortality during oral anticoagulant treatment. J Intern Med 271: 239-246.
31. Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, et al. (2011) Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 57: 2496-2504.
32. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, et al. (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124: 970-979.
33. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sorensen HT, (1997) Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 242: 497-503.
34. Palareti G, (2011) Bleeding with anticoagulant treatments. Hämostaseologie 31: 237-242.
35. Redwood M, Taylor C, Bain BJ, Matthews JH, (1991) The association of age with dosage requirement for warfarin. Age Ageing 20: 217-220.
36. Wickramasinghe LS, Basu SK, Bansal SK, (1988) Long-term oral anticoagulant therapy in elderly patients. Age Ageing 17: 388-396.
37. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, et al. (2011) Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 124: 824-829.
38. Rydz N, James PD (2012) The evolution and value of bleeding assessment tools. J Thromb Haemost doi: 10.1111/j.1538-7836.2012.04923.x.